Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

New England Journal of Medicine

Volumn 356, Issue 19, 2007, Pages 1915-1927

  Villa, Luisa L ^a   Perez, Gonzalo ^b   Kjaer, Susanne K ^c   Paavonen, Jorma ^d   Lehtinen, Matti ^e   Muñoz, Nubia ^f   Sigurdsson, Kristján ^g   Hernandez Avila, Mauricio ^h   Skjeldestad, Finn Egil ⁱ   Thoresen, Steinar ^j   García, Patricia ^k   Majewski, Slawomir ^l   Dillner, Joakim ^m   Olsson, Sven Eric ⁿ   Eng, Hseon Tay ^o   Bosch, F Xavier ^p   Ault, Kevin A ^q   Brown, Darron R ^r   Ferris, Daron G ^s   Koutsky, Laura A ^t   Kurman, Robert J ^u   Myers, Evan R ^v   Barr, Eliav ^w   Boslego, John ^w   Bryan, Janine ^w   Esser, Mark T ^w   Gause, Christine K ^w   Hesley, Teresa M ^w   Lupinacci, Lisa C ^w   Sings, Heather L ^w   Taddeo, Frank J ^w   Thornton, Annemarie R ^w   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^b National Research Center   (Colombia)

^c Rigshospitalet   (Denmark)

^d UNIVERSITY OF HELSINKI   (Finland)

^e NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^g ICELANDIC CANCER SOCIETY   (Iceland)

^h INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

ⁱ NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^j CANCER REGISTRY OF NORWAY   (Norway)

^k UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^l MEDICAL UNIVERSITY OF WARSAW   (Poland)

^m LUND UNIVERSITY   (Sweden)

ⁿ DANDERYD HOSPITAL   (Sweden)

^o KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

^p BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^q EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^r INDIANA UNIVERSITY   (United States)

^s MEDICAL COLLEGE OF GEORGIA   (United States)

^t UNIVERSITY OF WASHINGTON   (United States)

^u JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v DUKE UNIVERSITY MEDICAL CENTER   (United States)

^w MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT; UTERINE CERVIX CARCINOMA IN SITU; VIRUS STRAIN; WART VIRUS;

EID: 34248326338     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa061741     Document Type: Article

References (38)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. Lyon, France: IARC Press, 2004. (Accessed April 13, 2007, at http://www-dep.iarc.fr/ globocan/methods.htm.)
2. Insinga RP, Glass AG, Rush BB. The health care costs of cervical human papillomavirus-related disease. Am J Obstet Gynecol 2004;191:114-20.
3. Goldie SJ, Kuhn L, Denny L, Pollack A, Wright TC. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001;285:3107-15. [Erratum, JAMA 2001;286:1026.]
4. Muñoz N, Bosch FX, de Sanjosé S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
5. Preventive human papillomavirus (HPV) vaccines - regulatory briefing document on endpoints. V. Presented at the Vaccines and Related Biological Products Advisory Committee Meeting, Bethesda, MD, November 28-29, 2001. (Accessed April 13, 2007, at http://www.fda.gov/ohrms/dockets/ac/01/briefing/ 3805b1_01.htm.)
6. Pagliusi SR, Aguado TA. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004;23:569-78.
7. von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598-604.
8. Wiley DJ, Douglas J, Beutner K, et al. External genital warts: diagnosis, treatment, and prevention. Clin Infect Dis 2002;35:Suppl 2:S210-S224.
9. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
10. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 viruslike particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
11. Tavassoli FA, Devilee P, eds. Pathology and genetics: tumours of the breast and female genital organs. Lyon, France: IARC Press, 2003.
12. Tumors of the cervix, vagina and vulva. Atlas of tumor pathology. 3rd series. Fascicle 4. Washington, DC: Armed Forces Institute of Pathology, 1992:44-55.
13. Wang SK, Tsiatis AA. Approximately optimal one-parameter boundaries for group sequential trials. Biometrics 1987;43:193-9.
14. Chan ISF, Bohidar NR. Exact power and sample size for vaccine efficacy studies. Commun Stat Theory Methods 1998;27:1305-22.
15. Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002;359:1686-9.
16. European Surveillance of Congenital Anomalies home page. (Accessed April 13, 2007, at http://www.eurocat.ulster.ac.uk/.)
17. Benedet JL, Bender H, Jones H III, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. Int J Gynaecol Obstet 2000;70:209-62.
18. Peto J, Gilham C, Deacon J, et al. Cervical HPV infection and neoplasia in a large population-based prospective study: the Manchester cohort. Br J Cancer 2004;91:942-53.
19. ASCUS-LSIL Triage Study (ALTS) Group. A randomized trial on the management of low-grade squamous intraepithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-400.
20. Idem. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003;188:1383-92.
21. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ. 2001 Consensus Guidelines for the management of women with cervical cytological abnormalities. JAMA 2002;287:2120-9.
22. Ferris DG. The 2001 ASCCP management guidelines for cervical cytology. Am Fam Physician 2004;70:1866-8.
23. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection of human papillomavirus type 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
24. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001;357:1831-6.
25. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis 2005;191:731-8.
26. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
27. Schiffman MH. New epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1995;87:1345-7.
28. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27. [Erratum, Obstet Gynecol 2006;107:1425.]
29. Villa LL, Costa RLR, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
30. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized control trial. Lancet 2006;367:1247-55.
31. Olsson SE, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle vaccine. Vaccine (in press).
32. Lehtinen M, Herrero R, Mayaud P, et al. Chapter 28: Studies to assess the longterm efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006;24:Suppl 3:S233-S241.
33. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 2006;24:Suppl 3:S42-S51.
34. Chua K-L, Hjerpe A. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 1996;77:121-7.
35. Thomas KK, Hughes JP, Kuypers JM, et al. Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000;182:1097-102.
36. Liaw K-L, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001;183:8-15.
37. Rousseau M-C, Pereira JS, Prado JC, Villa LL, Rohan TE, Franco EL. Cervical coinfection with human papillomavirus (HPV) types as a predictor of acquisition and persistence of HPV infection. J Infect Dis 2001;184:1508-17.
38. Weissenborn SJ, Funke AM, Hellmich M, et al. Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated. J Clin Microbiol 2003;41:2763-7.